Finally, we identified known drug targets for non-cardiac diseases, including those that have been associated with adverse cardiac outcomes (for example, ABCC1 (target of abiraterone for prostate cancer) and DPP4 (target of sitagliptin for pancreatic beta cells in diabetes)). Here, DPP4 is linked to prostate carcinoma.